Evidence map›Paper›PMID 32899412›Full record

ReviewGenes2020

The Target of Rapamycin Signalling Pathway in Ageing and Lifespan Regulation.

Ivana Bjedov, Charalampos Rallis

Open access · goldAbstract readReview
In one paragraph

Review in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 106 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Functional analysis of target of rapamycin in regulating mycelial growth and development in Penicillium italicum.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Co-delivery of SN38 and rapamycin albumin bound nanoparticles against breast Cancer.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Ivana BjedovUCL Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6DD, UK.
Charalampos RallisSchool of Life Sciences, University of Essex, Wivenhoe Park, Colchester CO4 3SQ, UK.ORCID 0000-0002-4390-0266
CRUK Lung Cancer Centre of Excellence · GBUniversity of Essex · GB

Funding

Cancer Research UK 28990Cancer Research UK C416/A25145Medical Research Council MR/M02492X/1
6 · The paper itself

Abstract

Ageing is a complex trait controlled by genes and the environment. The highly conserved mechanistic target of rapamycin signalling pathway (mTOR) is a major regulator of lifespan in all eukaryotes and is thought to be mediating some of the effects of dietary restriction. mTOR is a rheostat of energy sensing diverse inputs such as amino acids, oxygen, hormones, and stress and regulates lifespan by tuning cellular functions such as gene expression, ribosome biogenesis, proteostasis, and mitochondrial metabolism. Deregulation of the mTOR signalling pathway is implicated in multiple age-related diseases such as cancer, neurodegeneration, and auto-immunity. In this review, we briefly summarise some of the workings of mTOR in lifespan and ageing through the processes of transcription, translation, autophagy, and metabolism. A good understanding of the pathway's outputs and connectivity is paramount towards our ability for genetic and pharmacological interventions for healthy ageing and amelioration of age-related disease.

Indexed as

AutophagyLongevityAgingAnimalsHumansSignal TransductionSirolimusTOR Serine-Threonine KinasesSirolimusTOR Serine-Threonine KinasesageingautophagyDrosophilametabolismnutrient-responseTORC1TORC2transcriptiontranslationyeast

Identifiers

PMID32899412
PMCPMC7565554
OpenAlexW3082206461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.